Application | Comment | Organism |
---|---|---|
medicine | promising target for drug development in anti-tumor therapies, ability of seven available docking programs to predict the binding mode and binding affinity of alpha-mannosidase II inhibitors | Drosophila melanogaster |
Crystallization (Comment) | Organism |
---|---|
GMII complexed with inhibitors (2R,3R,4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3,4-diol, (2R,3R,4S)-2-([[(1S)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3,4-diol, and (2R,3R,4S,5R)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-5-methylpyrrolidine-3,4-diol, to 1.30-1.45 A resolution | Drosophila melanogaster |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(1S,2R,6R,7R,8S,8aS)-octahydroindolizine-1,2,6,7,8-pentol | most active | Drosophila melanogaster | |
(2R,3R,4R,5R)-2-(hydroxymethyl)piperidine-3,4,5-triol | - |
Drosophila melanogaster | |
(2R,3R,4R,5R)-5-amino-2-(hydroxymethyl)piperidine-3,4-diol | - |
Drosophila melanogaster | |
(2R,3R,4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3,4-diol | - |
Drosophila melanogaster | |
(2R,3R,4S)-2-([[(1S)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3,4-diol | - |
Drosophila melanogaster | |
(2R,3R,4S,5R)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-5-methylpyrrolidine-3,4-diol | - |
Drosophila melanogaster | |
(2R,3R,4S,5S)-6-amino-2-(hydroxymethyl)-2,3,4,5-tetrahydropyridine-3,4,5-triol | - |
Drosophila melanogaster | |
(2R,3S,4R)-2-[(1R)-1-hydroxyethyl]pyrrolidine-3,4-diol | most active | Drosophila melanogaster | |
(2R,3S,4S)-1-[(2S,3S)-2,4-dihydroxy-3-(sulfooxy)butyl]-3,4-dihydroxy-2-(hydroxymethyl)tetrahydrothiophenium | - |
Drosophila melanogaster | |
(3R,4R)-4-aminopyrrolidin-3-ol | - |
Drosophila melanogaster | |
(5R,6R,7S,8R)-5-methyl-1,5,6,7,8,8a-hexahydrotetrazolo[1,5-a]pyridine-6,7,8-triol | - |
Drosophila melanogaster | |
(5R,6R,7S,8S)-5-(hydroxymethyl)-1,5,6,7,8,8a-hexahydroimidazo[1,2-a]pyridine-6,7,8-triol | - |
Drosophila melanogaster | |
5-thio-alpha-D-mannopyranosylamine | - |
Drosophila melanogaster | |
kifunensine | - |
Drosophila melanogaster | |
N-[(R)-amino(phenyl)methyl]-5-thio-alpha-D-mannopyranosylamine | - |
Drosophila melanogaster | |
salacinol | - |
Drosophila melanogaster | |
swainsonine | most active | Drosophila melanogaster |
Metals/Ions | Comment | Organism | Structure |
---|---|---|---|
Zn2+ | is involved in the catalytic activity of the enzyme and in the strong binding of inhibitors | Drosophila melanogaster |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Drosophila melanogaster | Q24451 | - |
- |
Synonyms | Comment | Organism |
---|---|---|
GmII | - |
Drosophila melanogaster |
Golgi alpha-mannosidase II | - |
Drosophila melanogaster |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.000017 | - |
- |
Drosophila melanogaster | swainsonine | |
0.72 | - |
- |
Drosophila melanogaster | (2R,3R,4S)-2-([[(1S)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3,4-diol | |
0.8 | - |
- |
Drosophila melanogaster | (2R,3R,4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3,4-diol | |
1 | - |
- |
Drosophila melanogaster | (2R,3R,4S,5R)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-5-methylpyrrolidine-3,4-diol |